News

2015

Flagship Pioneering and its portfolio companies make news because of their transformative approaches to solving global challenges. If you have needs beyond these resources, please contact press@flagshippioneering.com.

company

year

domain

Seres Therapeutics Announces Initiation of a Phase 1b Clinical Trial of SER-287 in Mild-to-Moderate Ulcerative Colitis

Seres Therapeutics 12.14.2015

Seres Therapeutics Appoints Kurt Graves to Board of Directors

Seres Therapeutics 11.10.2015

Seres Therapeutics, Inc. Announces FDA Orphan Drug Designation for SER-109 for the Prevention of Recurrent Clostridium Difficile Infection in Adults

Seres Therapeutics 08.21.2015

Seres Therapeutics Reports Second Quarter 2015 Financial Results and Provides Business Update

Seres Therapeutics 08.06.2015

Seres Therapeutics, Inc. Announces Pricing of Initial Public Offering

Seres Therapeutics 06.25.2015

Seres Therapeutics Receives FDA Breakthrough Therapy Designation for Its Lead Product Candidate, SER-109

Seres Therapeutics 06.12.2015

Seres Therapeutics, Inc. Elects Dennis Ausiello, M.D., to Board of Directors

Seres Therapeutics 06.11.2015

Seres Health Announces Addition of Mark Wilcox, M.D. to Scientific Advisory Board

Seres Therapeutics 01.21.2015

Seres Health Appoints Shelley Trucksis, Ph.D., M.D. as Executive Vice President and Chief Medical Officer

Seres Therapeutics 01.15.2015

Loading